Literature DB >> 15546964

Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis.

L Teixeira1, A Mahr, F Jaureguy, L-H Noël, H Nunes, A Lefort, S Barry, P Deny, L Guillevin.   

Abstract

OBJECTIVES: Recently published findings suggested that antineutrophil cytoplasmic antibodies (ANCA), particularly those with a cytoplasmic (C-ANCA) labelling pattern and targeting proteinase 3 (anti-PR3), might be markers of tuberculosis (TB). This is a critical issue, because C-ANCA/anti-PR3 were considered to be a highly specific hallmark of Wegener's granulomatosis or microscopic polyangiitis and because TB may clinically mimic Wegener's granulomatosis. We therefore undertook a study with the aim of investigating further the prevalence and specificity of ANCA in TB.
METHODS: We evaluated serum samples from 67 patients diagnosed with culture-proven TB and 10 previously untested control samples from patients known to be ANCA positive (four Wegener's granulomatosis and two microscopic polyangiitides) or negative. All 77 sera were screened for ANCA using commercially available indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) for anti-PR3 and antimyeloperoxidase (MPO). IIF-positive and anti-PR3- and anti-MPO-negative sera were also tested for bactericidal/permeability-increasing protein, lactoferrin, elastase and cathepsin G specificities with commercially available ELISA.
RESULTS: IIF detected ANCA in seven (10%) of the TB sera, including three C-ANCA and four atypical perinuclear-labelling ANCA. Only one IIF-negative specimen was anti-PR3 positive in ELISA. ANCA testing of the control sera yielded IIF and ELISA results concordant with previous findings, except for one borderline ELISA.
CONCLUSION: Our results indicate that TB is associated with low ANCA seroprevalence and poor specificity, with no test serum showing combined C-ANCA/anti-PR3 activity. In a clinical setting of Wegener's granulomatosis/TB mimicry, such combined reactivity would seem to be more suggestive of Wegener's granulomatosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546964     DOI: 10.1093/rheumatology/keh467

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis.

Authors:  I Lima; R C Oliveira; M S Cabral; A Atta; S Marchi; E Reis; M G Reis; L Barbosa; M B Santiago
Journal:  Rheumatol Int       Date:  2014-04-10       Impact factor: 2.631

Review 2.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

3.  Background noise of infection for using ANCA as a diagnostic tool for vasculitis in tropical and developing countries.

Authors:  Kanjaksha Ghosh; Vandana Pradhan; Kinjalka Ghosh
Journal:  Parasitol Res       Date:  2008-02-24       Impact factor: 2.289

4.  Pulmonary tuberculosis presenting as diffuse alveolar hemorrhage: Believe it or not.

Authors:  Alkesh Kumar Khurana; Sourabh Jain; Abhishek Goyal; Saurabh Saigal; Ujjawal Khurana
Journal:  Lung India       Date:  2018 Nov-Dec

5.  Myeloperoxidase-antineutrophil Cytoplasmic Antibodies with Cytoplasmic Fluorescence Pattern.

Authors:  Seema Chhabra; Ranjana Walker Minz; Lekha Goyal; Nidhi Sharma
Journal:  J Lab Physicians       Date:  2010-01

6.  The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis.

Authors:  Ori Elkayam; Daniele Bendayan; Refael Segal; Yinon Shapira; Boris Gilburd; Sandra Reuter; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Rheumatol Int       Date:  2012-08-04       Impact factor: 3.580

7.  Pulmonary granulomas in a patient with positive ANCA and history of tuberculosis: case report.

Authors:  B Wong; E Tan; A McLean-Tooke
Journal:  BMC Pulm Med       Date:  2020-08-14       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.